We could not find any results for:
Make sure your spelling is correct or try broadening your search.
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. 2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer.
Abecma generated $77 million U.S. commercial revenue, growing 42% versus the second quarter Decision in September to discontinue enrollment in KarMMa-9 study results in over $80 million in...
2seventy bio, Inc. (Nasdaq: TSVT) will announce its third quarter 2024 financial results on Tuesday, November 12, 2024. A conference call and webcast will be held at 8:00 a.m. ET. Participants...
2seventy and Bristol Myers Squibb discontinue enrollment in Phase 3 KarMMa-9 study Decision results in over $80 million in anticipated cost savings for 2seventy over the next several years and...
2seventy bio, Inc. (Nasdaq: TSVT), announced today that members of the management team will participate in a fireside chat at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.26 | -5.65217391304 | 4.6 | 5.12 | 4.3 | 542582 | 4.9079736 | CS |
4 | -0.64 | -12.8514056225 | 4.98 | 5.3 | 4.3 | 306435 | 4.88265566 | CS |
12 | -0.38 | -8.05084745763 | 4.72 | 5.3 | 4.21 | 297042 | 4.77447725 | CS |
26 | -0.13 | -2.90827740492 | 4.47 | 5.3 | 3.54 | 396637 | 4.45130627 | CS |
52 | 2.15 | 98.1735159817 | 2.19 | 6.4 | 1.535 | 959446 | 4.05987563 | CS |
156 | -34.19 | -88.7360498313 | 38.53 | 39.99 | 1.535 | 810840 | 8.1031105 | CS |
260 | -21.79 | -83.3907386146 | 26.13 | 44.34 | 1.535 | 810590 | 8.287412 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions